Table 3.

Estimated probabilities (95% confidence interval) of virologic outcome

Outcome*
		LPV/r BID	LPV/r QD	Difference
SVR† (Intent-to-treat)	Overall	0.81 ( 0.73, 0.86)	0.78 (0.70, 0.84)	0.03 (−0.07, 0.12)
	<100,000 cp/mL	0.72 ( 0.59, 0.81)	0.80 ( 0.69, 0.88)	−0.09 (−0.23, 0.06)
	≥100,000 cp/mL	0.89 ( 0.79, 0.94)	0.76 ( 0.64, 0.84)	0.13 (0.01, 0.25)
SVR† (As-treated)	Overall	0.85 ( 0.78, 0.90)	0.85 ( 0.78, 0.90)	0 (−0.09, 0.09)
	<100,000 cp/mL	0.80 ( 0.67, 0.88)	0.86 ( 0.75, 0.93)	−0.07 (−0.20, 0.07)
	≥100,000 cp/mL	0.90 ( 0.80, 0.95)	0.84 ( 0.73, 0.91)	0.06 (−0.06, 0.17)
Regimen completion‡	Overall	0.66 ( 0.58, 0.73)	0.61 ( 0.53, 0.68)	0.05 (−0.05, 0.16)
	<100,000 cp/mL	0.58 ( 0.47, 0.69)	0.61 ( 0.49, 0.71)	−0.02 (−0.18, 0.13)
	≥100,000 cp/mL	0.73 ( 0.62, 0.81)	0.61 ( 0.50, 0.71)	0.12 (−0.02, 0.26)
HIV-1 RNA <200 cp/mL	Overall	0.87 ( 0.81, 0.93)	0.81 ( 0.74, 0.88)	0.06 (−0.03, 0.15)
	<100,000 cp/mL	0.82 ( 0.72, 0.91)	0.80 ( 0.70, 0.90)	0.02 (−0.12, 0.15)
	≥100,000 cp/mL	0.91 ( 0.84, 0.98)	0.82 ( 0.73, 0.91)	0.09 (−0.02, 0.20)

^*Based on Kaplan-Meier estimates and of having an HIV-1 RNA result <200 copies/mL at week 48 based on a cross-sectional analysis (missing data excluded), and corresponding differences with 95% CI overall and by screening HIV-1 RNA level

^†Sustained virologic response (SVR) defined as remaining free of virologic failure. Virologic failure = any one of the following three occurrences: confirmed HIV-1 RNA ≥200 cp/mL after two consecutive HIV-1 RNA <200 cp/mL (confirmed relapse); confirmed HIV-1 RNA ≥200 cp/mL at or after visit week 24 without prior viral relapse; HIV-1 RNA ≥200 cp/mL at visit week 48, which did not require confirmation

^‡Regimen completion = virologic failure or discontinuation of initially randomized LPV/r dose schedule, whichever occurred earlier